Selecta Biosciences Inc
NASDAQ:SELB
| Market Cap (Intraday) | 455.70M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $4.10 |
| 50-Day MA | $4.22 |
| 200-Day MA | $4.07 |
Selecta Biosciences Inc Stock, NASDAQ:SELB
480 Arsenal Way, 65 Grove Street, Watertown, Massachusetts 02472
United States of America
Phone: +1.617.923.1400
Number of Employees: 43
Description
Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm's proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.